Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940 (DCA) is India’s central law that regulates the import, manufacture, distribution, and sale of drugs and cosmetics. Its purpose is simple yet vital: protect public health by ensuring that products are safe, effective, and of standard quality. Paired with the Drugs and Cosmetics Rules, 1945, it creates a practical framework for classification, storage, sale, display, and prescription of medicines across the country.

This guide explains the Act in plain language. The focus is on what the law expects from manufacturers, distributors, pharmacies, and inspectors, and what consumers and professionals should know.

Why this Drugs and Cosmetics Act, 1940 Matters

• Protects consumers from adulterated, spurious, and misbranded products.
• Ensures only qualified persons handle the trade in drugs/cosmetics.
• Brings Ayurveda, Siddha and Unani (ASU) systems within a regulatory fold.
• Sets up central bodies for technical advice, coordination, and testing.
• Enables inspections, sampling, prosecutions, and special courts for offences.

Background & evolution of Drugs and Cosmetics Act, 1940

• 1930: The Chopra Committee recommended a national law on drugs.
• 1940: Parliament enacted the law (originally called the Drug Act).
• 1945: Drugs and Cosmetics Rules framed; the Act took its present, operational shape.
• 1964: Major amendment added Ayurveda & Unani drugs to the Act.
• Multiple amendments since then to address quality, labelling, enforcement, and penalties.

Scope & applicability of Drugs and Cosmetics Act, 1940

The Act covers drugs and cosmetics across the supply chain—import, manufacture, sale, stock, exhibit, and distribution. The Rules provide detailed conditions and Schedules that dictate how products are stored, displayed, and dispensed.

Key definitions under Drugs and Cosmetics Act, 1940

Drug (Sec. 3)

Includes:

• Medicines for internal/external use; substances used for diagnosis, treatment, mitigation, or prevention of disease in humans/animals (this extends to items like mosquito repellents).
• Non-food substances affecting body structure/function; substances to destroy disease-causing insects/vermin, as notified.
• Components of a drug (e.g., empty gelatin capsules).
• Devices used on humans/animals for diagnosis/treatment etc., as notified after consulting DTAB.

Cosmetic (Sec. 3)

Articles applied/sprayed/rubbed on the human body for cleansing, beautifying, promoting attractiveness or altering appearance, and their components. Soaps are excluded from this definition.

Misbranded drug

A drug is misbranded if:

• It is not labelled as prescribed; or
• Is coloured/coated/polished to conceal damage or exaggerate value; or
• Its label/pack/insert carries a false or misleading claim.

Adulterated drug (Sec. 9A)

For example, if a product:

• Contains filthy/putrid/decomposed matter; or
• Is prepared/packed/stored in unsanitary conditions; or
• Has a poisonous container; or
• Uses an unprescribed colour; or
• Contains harmful/toxic substances; or
• Is mixed to reduce quality/strength.

Spurious drug (Sec. 17B)

Covers imitations, substitutions, deceptive resemblance, use of fictitious manufacturer names, or false origin claims.

ASU drugs & patent/proprietary medicines

• ASU drugs: Must follow authoritative texts listed in the First Schedule.
• Patent/proprietary medicine:
  • For ASU: formulations only with ingredients from the authoritative books (parenterals excluded).
  • For other systems (including allopathy): ready-to-use products not included in a pharmacopoeia.

“Manufacture”

Covers processes like making, altering, packing, labelling, etc., for sale/distribution. It excludes ordinary retail compounding or dispensing.

The three wings: who does what under Drugs and Cosmetics Act, 1940

Advisory wing

Drugs Technical Advisory Board (DTAB)

• Statutory technical body advising Central/State Governments on all technical matters under the Act/Rules.
• 18 members (ex-officio, elected, nominated) from medical and pharmacy fields.
• Chair: Director General of Medical & Health Services (GoI).
• Member-Secretary: Drugs Controller General of India (DCGI).
• Meets twice a year; can form sub-committees; urgent Ministry decisions must be ratified within 6 months.
• Sets the technical backbone for standards and specifications.

Drugs Consultative Committee (DCC) (Sec. 7)

• Ensures uniform implementation of the Act/Rules across States/UTs.
• Advises Centre/States/DTAB; typically includes State Drug Controllers as members.

Analytical wing

Central Drug Laboratory (CDL), Kolkata (Sec. 6)

• The statutory analytical laboratory. Its analysis reports carry finality in court proceedings.
• Functions:
  • Analyse samples from Customs and courts.
  • Undertake analytical work and R&D in testing methodologies.
  • Advise Centre/States/UTs; may accept fee-based private/consumer samples.

Government Analysts

• Appointed at CDL and State/UT labs.
• Duties include verifying seals/custody, analysing samples, and issuing triplicate reports on prescribed forms.

Administrative wing

DCGI, State Drugs Control & Licensing Authorities, and Drug Inspectors (Central/State).

They administer licences, inspections, sampling, and prosecutions.

Sections every practitioner should know

Powers, inspections, and procedures

Drug Inspectors: appointment & qualifications

• Appointed by Centre/States for specific areas or activities; deemed public servants.
• Must hold relevant degrees (pharmacy/pharmaceutical sciences/medicine with specialisation) and have experience for certain categories (e.g., Schedules C & C(1)).

Duties—premises licensed for sale

• Annual inspection of each sale establishment.
• Verify licence conditions and records.
• Lift samples for testing where violations are suspected.
• Investigate complaints and initiate prosecutions where warranted.
• Detain prohibited imports when authorised.

Duties—manufacturing units (specially authorised)

• Annual inspection of licensed manufacturers.
• Examine plant/process/standardisation/storage/technical staff (especially for C & C(1) products).
• Collect samples; file detailed inspection reports; maintain confidentiality.
• Power to seize records and stop sale up to 20 days on reasonable belief of violations.

Sampling & seizure (the practical flow)

• Shops: divide samples into four parts—Inspector, Government Analyst, Dealer, Manufacturer (injectables: four ampoules of the same batch).
  
• Pay fair price/issue receipt; seal with both seals; immediately inform the Judicial Magistrate.
• Send to Government Analyst in a sealed packet with memorandum; separately post the seal impression.
• Manufacturers: prepare three samples—Inspector/Court, Manufacturer, Analyst.
• Assault or threats against an inspector on duty are punishable (including imprisonment).

Why these steps matter: Proper chain-of-custody and paperwork protect both sides—ensuring that evidence stands in court and genuine businesses are not harassed.

Licensing & the licensing authority

Each licensing authority member must be suitably qualified and experienced in manufacture/testing. Core duties include:

• Inspect every drug-selling establishment in their jurisdiction.
• Enforce licence conditions; verify stock, storage, and records.
• Send imported packages for test/analysis where needed.
• Investigate complaints; keep a paper trail of inspections and actions.
• Detect and act on unlicensed or non-compliant sales.

Import control: what is allowed, and what is not

Personal use

• Travellers may bring up to 100 doses in baggage without a licence, subject to declaration if asked.
• For more than 100 doses, obtain a licence (prescribed forms apply).
• Must be bona fide personal use.

For examination, test, or analysis

• Requires a Form 11 licence; use only at the specified site.
• Maintain records (quantity, manufacturer, date of import).
• Allow inspectors to check premises and records.

Imports that do not require a licence

• Substances not used for medicinal purposes.
• Certain Schedule C items needed for manufacturing.
• Specific dual-use foods (e.g., pre-digested foods), as permitted.

Prohibited imports (illustrative)

• Substandard, misbranded, counterfeit/spurious, or adulterated products.
• Items that require a licence but are imported without one.
• Patent/proprietary medicines lacking a true formula/active list.
• Products claiming to treat diseases listed in Schedule J.
• Items illegal in country of origin.
• Non-compliant labelling/packing.
• Unsafe cosmetics.

Penalties (import-related)

• Adulterated/spurious imports: up to 3 years’ imprisonment and fine (as specified).
• Other illegal imports: up to 6 months’ imprisonment and fine (or both).
• Imports contrary to specific government notifications may attract up to 3 years’ imprisonment or fine.

Note: For other serious offences (e.g., manufacture/sale of spurious or adulterated drugs), the Act contemplates stricter penalties, including higher fines and, in aggravated scenarios, imprisonment up to life. Always consult the current text of the Act/Rules for the exact position.

The Drugs and Cosmetics Rules, 1945

The Rules make the Act workable. They:

• Classify drugs into Schedules.
• Set conditions for storage, sale, display, and prescription.
• Prescribe labelling standards (e.g., Rule 97).
• Set licence conditions (e.g., Rule 67G).
• Affirm DTAB as the apex body for technical specifications.

Practical tip: Retailers and wholesalers should train staff on the Schedules relevant to their stock, maintain prescription records where required, and follow temperature/humidity guidelines for storage.

New Drugs and Clinical Trial Rules, 2019 (at a glance)

• Notified to promote clinical research and streamline new drug approvals.
• Cover topics like orphan drugs, post-trial access, and pre/post-submission meetings.
• Organised into 13 Chapters, 107 Rules, and 8 Schedules.
• Apply to human biologicals (e.g., vaccines, r-DNA products).
• Excluded: stem cell/cell-based products and veterinary vaccines.

Why this matters: The 2019 Rules modernise clinical trial governance and aim to improve timelines and clarity for sponsors and investigators, while emphasising participant protection.

Case law that clarifies the Drugs and Cosmetics Act, 1940

Sri G. Ramesh Reddy v. State by Drugs Inspector (2013)

• Context: Liability of a company director when drugs are found substandard.
• Holding: Merely being a director is not enough to prosecute. There must be prima facie evidence linking the director’s specific acts to the offence.

Takeaway: Prosecution should focus on responsible persons actually in charge of the conduct of business at the time of the offence.

State of Karnataka v. S. B. Shivashankar (2018)

• Context: Sale of scheduled drugs without prescription and without a registered pharmacist; no sale bill. Conviction entered.
• Issue on appeal: State sought a harsher sentence; argued minimum fine should be higher.
• Holding: Appeal dismissed—the trial court had accepted plea bargaining; sentence flowed from that. No interference warranted.

Takeaway: Once plea bargaining is properly recorded and accepted, appellate courts are slow to revise the sentence unless there is a clear legal error.

A known gap: penalties for clinical trial violations

A major criticism has been the lack of specific penalties under the DCA for some clinical trial violations. In one high-profile matter involving HPV vaccination trials among tribal girls, the government informed the Supreme Court that it could halt trials and issue warnings, but explicit penalty provisions under the DCA were inadequate. This gap is one reason clinical-trial–specific rules and future legislative reforms have been emphasised.

The Drugs, Medical Devices and Cosmetics Bill, 2022 (draft)

To respond to evolving technology and market realities, a draft comprehensive Bill (2022) was floated for public consultation. Key proposals include:

• A modern definition and regulatory regime for medical devices with a dedicated regulator.
• Broader import oversight for devices.
• Clearer regulation for AYUSH products.
• Explicit clinical trial provisions within the primary statute.
• Online pharmacies brought under a transparent framework.
• Enhanced penalties to strengthen deterrence.

Status note: As a draft measure, it signals policy direction. Stakeholders should track how the final text shapes responsibilities for devices, e-pharmacies, and trials.

Compliance checklists (practical)

For manufacturers

• Maintain valid manufacturing licences for all products/sites.
• Ensure GMP-like controls over premises, process validation, stability, and documentation.
• Adhere to labelling standards and include true formula/actives.
• Keep batch records, change control, and recall procedures ready.
• Facilitate inspections; cooperate with inspectors; keep samples and test reports.
• For ASU products, match formulations to authoritative texts.

For wholesalers/retail pharmacies

• Keep sale licences current; display them.
• Store drugs per temperature/humidity recommendations.
• Dispense prescription-only drugs only against valid prescriptions; maintain records where required.
• Train staff; ensure presence of a registered pharmacist where mandated.
  
• Maintain purchase/sale registers; be ready for annual inspections.
• Cooperate during sampling; follow the sealing and memo process.

For importers

• Verify if the product needs a licence; obtain Form 11 for test/analysis imports.
• For personal use consignments, stick to dose limits and declare when asked.
• Avoid importing prohibited items (e.g., misbranded/spurious/adulterated; products non-compliant with labelling; those illegal in country of origin).
• Keep manufacturer details, quantities, dates in order for inspection.

Forms you will encounter

Labelling & advertising: quick reminders

• Follow the prescribed labelling format (names, strengths, batch, mfg/exp dates, actives).
• Avoid false, exaggerated, or misleading therapeutic claims—this triggers misbranding consequences.
• Do not claim cures for diseases restricted by Schedule J.
• For cosmetics, ensure permitted colours and proper labelling; avoid unsafe ingredients.

Penalties & prosecution

• The Act prescribes graded penalties based on the nature of offence—ranging from fines to imprisonment.
• Some offences are cognisable and non-bailable; special courts can be notified for speedier trials.
• The Act also permits aggregation of minor offences in certain situations to reduce procedural overload.
• Import-related offences carry their own penalty slabs.
• For grave offences involving spurious/adulterated products, penalties can be stringent, with higher fines and, in aggravated cases, imprisonment up to life.
  

Conclusion

The Drugs and Cosmetics Act, 1940 remains the cornerstone of India’s pharmaceutical and cosmetics regulation. Its definitions, technical bodies (DTAB/DCC), testing infrastructure (CDL and State labs), and administrative machinery (DCGI, State authorities, inspectors) work together to keep unsafe, misbranded, or spurious products off the market.

For businesses, compliance is not just about licences—it’s about robust processes, accurate labels, clean records, and cooperation with inspectors. For consumers, the Act provides a safety net by insisting on quality standards and enabling strong enforcement. And as the sector evolves, the 2019 Clinical Trial Rules and the 2022 draft Bill show a clear policy direction: modernisation, transparency, and deterrence.